Lower steroid use in active lupus kidney inflammation
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 80
- You have lupus (systemic lupus erythematosus) diagnosed by standard criteria
- Your kidney disease is biopsy-confirmed proliferative lupus nephritis (class III or IV, sometimes with class V)
- Your kidney function fits one of these: eGFR over 30, or 15–30 with low long-term scarring (NIH chronicity index under 6)
- You can safely take medicines like methylprednisolone, mycophenolate, mouth steroids, or rituximab (no major contraindications)
- You can give informed consent and are able to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This study tests a new combination of two medicines (rituximab and a low dose of mycophenolate mofetil) to help children with active lupus nephritis (kidney inflammation from lupus). The goal is to see if combining these drugs works better and is safe for children.
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
This study is looking for biomarkers (clues in your blood, urine, or tissue) that can help predict how well lupus nephritis (kidney inflammation caused by lupus) responds to treatment. It focuses on people who have active kidney disease and are either starting treatment or have been on a stable treatment for at least a month.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.